We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
[Experimental study of anti-VEGF hairpin ribozyme gene inhibiting expression of VEGF and proliferation of ovarian cancer cells].
Ai Zheng = Aizheng = Chinese Journal of Cancer 2002 January
BACKGROUND & OBJECTIVE: Growth of solid tumor metastases are critically dependent on angiogenesis. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, has been identified as one of the most potent inducers of tumor associated angiogenesis, studies have shown that VEGF plays an important role in angiogenesis which is associated with epithelial ovarian cancer. Until now, many strategies for gene therapy have been developed. Among them is Ribozyme-based therapeutics for cancer which might be devised to inhibit tumor growth or prevent metastases. Angiogenesis is required for sustained tumor growth, making the VEGF pathway another promising target for either small molecule or nucleic acid-based therapeutics. Little is known about the role of VEGF in ovarian tumorigenecity. We propose to block the autocrine and/or paracrine pathway of VEGF in ovarian cancer using anti-VEGF hairpin ribozyme gene to see whether the growth of tumor cells could be inhibited and to further exploit its mechanisms.
METHODS: Anti-VEGF hairpin ribozyme gene eukaryotic expression vector was introduced into ovarian cancer SKOV3 cells by lipofectin mediation and positive clones were screened by G418; Ribozyme expression was confirmed by RNA dot blot; The VEGF expression of SKOV3 cells before or after transfection were detected by immunohistochemical and immunofluorescence and flow cytometer immunofluorescence methods, MTT, colony forming, soft agar colony forming, and FCM were used to observe the effect of proliferation to ovarian cancer cells.
RESULTS: VEGF expression decreased distinctly in SKOV3-RZ cells. The growth of transfected SKOV3-RZ cells were slower, The average colony forming efficiency and soft agar colony forming efficiency of SKOV3-RZ cells(12.7 +/- 1.4 and 9.4 +/- 2.0, respectively) decreased distinctly (P < 0.001). The SKOV3-RZ cells of G1 stage increased(P < 0.01), the SKOV3-RZ cells of S stage were reduced(P < 0.01).
CONCLUSIONS: Anti-VEGF hairpin ribozyme gene can inhibit the proliferation of ovarian cancer SKOV3 cells. This provides a experimental basis for cure human ovarian cancer with antiangiogenesis method.
METHODS: Anti-VEGF hairpin ribozyme gene eukaryotic expression vector was introduced into ovarian cancer SKOV3 cells by lipofectin mediation and positive clones were screened by G418; Ribozyme expression was confirmed by RNA dot blot; The VEGF expression of SKOV3 cells before or after transfection were detected by immunohistochemical and immunofluorescence and flow cytometer immunofluorescence methods, MTT, colony forming, soft agar colony forming, and FCM were used to observe the effect of proliferation to ovarian cancer cells.
RESULTS: VEGF expression decreased distinctly in SKOV3-RZ cells. The growth of transfected SKOV3-RZ cells were slower, The average colony forming efficiency and soft agar colony forming efficiency of SKOV3-RZ cells(12.7 +/- 1.4 and 9.4 +/- 2.0, respectively) decreased distinctly (P < 0.001). The SKOV3-RZ cells of G1 stage increased(P < 0.01), the SKOV3-RZ cells of S stage were reduced(P < 0.01).
CONCLUSIONS: Anti-VEGF hairpin ribozyme gene can inhibit the proliferation of ovarian cancer SKOV3 cells. This provides a experimental basis for cure human ovarian cancer with antiangiogenesis method.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app